The new patent not only covers methods to treat presbyopia, but is also applicable to treat other eye conditions including cataracts, glaucoma and retinal disorders.
Biolase Technology chairman and CEO Federico Pignatelli said they are demonstrating a number of strategic alternatives for their valuable ophthalmology technology embodied in the Er,Cr:YSGG Occulase MD laser system that they are currently working to market under their Occulase subsidiary.
"In addition to ophthalmology, we are assessing several other major medical applications in aesthetics, dermatology, ENT, orthopedics podiatry and pain management for our laser technologies," Pignatelli said.
